Meta[131I]iodobenzylguanidine therapy for patients with metastatic and unresectable pheochromocytoma and paraganglioma

Nuclear Medicine and Biology

Volumn 35, Issue SUPPL.1, 2008, Pages

  Goldsby, Robert E ^a   Fitzgerald, Paul A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Malignant; MIGB; Paragangliomas; Pheochromocytomas; Treatment

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; (3 IODOBENZYL)GUANIDINE I 124; (3 IODOBENZYL)GUANIDINE I 131; ANGIOTENSIN RECEPTOR ANTAGONIST; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM CHANNEL BLOCKING AGENT; CHROMOGRANIN A; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXORUBICIN; FLUORODEOXYGLUCOSE F 18; LABETALOL; MAGNESIUM SULFATE; MEDRONATE TECHNETIUM TC 99M; METADRENALIN; METIROSINE; METOPROLOL; NICARDIPINE; NIFEDIPINE; NITROPRUSSIDE SODIUM; PENTETREOTIDE IN 111; PHENOXYBENZAMINE; PHENTOLAMINE; PROTEIN RET; RADIOPHARMACEUTICAL AGENT; SUCCINATE DEHYDROGENASE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE;

ACUTE LUNG INJURY; ADULT RESPIRATORY DISTRESS SYNDROME; ANEMIA; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; AUTOPSY; BONE MARROW SUPPRESSION; BONE METASTASIS; BONE SCINTISCANNING; BRONCHIOLITIS OBLITERANS ORGANIZING PNEUMONIA; CANCER DIAGNOSIS; CANCER STAGING; CANDIDIASIS; CATECHOLAMINE EXCRETION; COMPUTER ASSISTED TOMOGRAPHY; CRYSTALLURIA; CYTOPENIA; DIAGNOSTIC IMAGING; DIAGNOSTIC PROCEDURE; ENGRAFTMENT SYNDROME; EXTERNAL BEAM RADIOTHERAPY; FATIGUE; FEMALE HYPOGONADISM; FOLLOW UP; GENE MUTATION; GENETIC PREDISPOSITION; GERM LINE; HAIR DISEASE; HAIR THINNING; HEMATOPOIETIC STEM CELL; HUMAN; HYPERTENSION; HYPOGONADISM; INFERTILITY; LABORATORY TEST; LEUKAPHERESIS; LEUKEMIA; LYMPHOCYTOPENIA; MALE INFERTILITY; MEDICAL LITERATURE; METASTASIS; MUTATION; MYELODYSPLASIA; MYELODYSPLASTIC SYNDROME; NEUROFIBROMATOSIS; NEUROPATHY; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PARAGANGLIOMA; PHEOCHROMOCYTOMA; POSITRON EMISSION TOMOGRAPHY; PROTO ONCOGENE; RADIOISOTOPE THERAPY; RARE DISEASE; REVIEW; SIALOADENITIS; SIPPLE SYNDROME; THROMBOCYTOPENIA; THRUSH; TREATMENT RESPONSE; VON HIPPEL LINDAU DISEASE; XEROSTOMIA;

EID: 49049114712     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2008.05.005     Document Type: Review

References (72)

1. Beard C.M., Sheps S.G., Kurland L.T., Carney J.A., and Lie J.T. Occurrence of pheochromocytoma in Rochester, Minnesota, 1950 through 1979. Mayo Clin Proc 58 (1983) 802-804
2. Stenstrom G., and Svardsudd K. Pheochromocytoma in Sweden 1958-1981. An analysis of the National Cancer Registry Data. Acta Med Scand 220 (1986) 225-232
3. Barontini M., Levin G., and Sanso G. Characteristics of pheochromocytoma in a 4- to 20-year-old population. Ann N Y Acad Sci 1073 (2006) 30-37
4. Madani R., Al-Hashmi M., Bliss R., and Lennard T.W. Ectopic pheochromocytoma: does the rule of tens apply?. World J Surg 31 (2007) 849-854
5. Yuan W.Q., Wang W.Q., Su T.W., Chen H.T., Shi Z.W., Fang W.Q., et al. A primary right atrium paraganglioma in a 15-year-old patient. Endocrine 32 (2007) 245-248
6. Eisenhofer G., Bornstein S.R., Brouwers F.M., Cheung N.K., Dahia P.L., de Krijger R.R., et al. Malignant pheochromocytoma: current status and initiatives for future progress. Endocr Relat Cancer 11 (2004) 423-436
7. Shen W.T., Sturgeon C., Clark O.H., Duh Q.Y., and Kebebew E. Should pheochromocytoma size influence surgical approach? A comparison of 90 malignant and 60 benign pheochromocytomas. Surgery 136 (2004) 1129-1137
8. Manger W.M. An overview of pheochromocytoma: history, current concepts, vagaries, and diagnostic challenges. Ann N Y Acad Sci 1073 (2006) 1-20
9. Zelinka T., Eisenhofer G., and Pacak K. Pheochromocytoma as a catecholamine producing tumor: implications for clinical practice. Stress 10 (2007) 195-203
10. Khorram-Manesh A., Jansson S., Wangberg B., Nilsson O., Tisell L.E., and Ahlman H. Mortality associated with pheochromocytoma: increased risk for additional tumors. Ann N Y Acad Sci 1073 (2006) 444-448
11. Amar L., Bertherat J., Baudin E., Ajzenberg C., Bressac-de Paillerets B., Chabre O., et al. Genetic testing in pheochromocytoma or functional paraganglioma. J Clin Oncol 23 (2005) 8812-8818
12. Neumann H.P., Bausch B., McWhinney S.R., Bender B.U., Gimm O., Franke G., et al. Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med 346 (2002) 1459-1466
13. Amar L., Baudin E., Burnichon N., Peyrard S., Silvera S., Bertherat J., et al. Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas. J Clin Endocrinol Metab 92 (2007) 3822-3828
14. Peczkowska M., Cascon A., Prejbisz A., Kubaszek A., Cwikla B.J., Furmanek M., et al. Extra-adrenal and adrenal pheochromocytomas associated with a germline SDHC mutation. Nat Clin Pract Endocrinol Metab 4 (2008) 111-115
15. Neumayer C., Moritz A., Asari R., Weinhausel A., Holzenbein T., Kretschmer G., et al. Novel SDHD germ-line mutations in pheochromocytoma patients. Eur J Clin Invest 37 (2007) 544-551
16. Kaelin W.G. Von Hippel-Lindau disease. Annu Rev Pathol 2 (2007) 145-173
17. Bausch B., Borozdin W., Mautner V.F., Hoffmann M.M., Boehm D., Robledo M., et al. Germline NF1 mutational spectra and loss-of-heterozygosity analyses in patients with pheochromocytoma and neurofibromatosis type 1. J Clin Endocrinol Metab 92 (2007) 2784-2792
18. Omura M., Saito J., Yamaguchi K., Kakuta Y., and Nishikawa T. Prospective study on the prevalence of secondary hypertension among hypertensive patients visiting a general outpatient clinic in Japan. Hypertens Res 27 (2004) 193-202
19. van der Kleij F.G. Adult respiratory distress syndrome due to pheochromocytoma as the initial presentation of multiple endocrine neoplasia type IIA syndrome. Am J Med 107 (1999) 401
20. Mok C.C., Ip T.P., and So C.C. Phaeochromocytoma with adult respiratory distress syndrome mimicking septicaemic shock. Med J Aust 166 (1997) 634-635
21. Shimizu C., Kubo M., Takano K., Takano A., Kijima H., Saji H., et al. Interleukin-6 (IL-6) producing phaeochromocytoma: direct IL-6 suppression by non-steroidal anti-inflammatory drugs. Clin Endocrinol (Oxf) 54 (2001) 405-410
22. Takagi M., Egawa T., Motomura T., Sakuma-Mochizuki J., Nishimoto N., Kasayama S., et al. Interleukin-6 secreting phaeochromocytoma associated with clinical markers of inflammation. Clin Endocrinol (Oxf) 46 (1997) 507-509
23. Sizemore G.W., Scrogin K.E., Weisenberg E.S., Weldon-Linne C.M., and Madoo O.B. Hypertensive crisis, catecholamine cardiomyopathy, and death associated with pseudoephedrine use in a patient with pheochromocytoma. Endocr Pract 14 (2008) 93-96
24. Rosas A.L., Kasperlik-Zaluska A.A., Papierska L., Bass B.L., Pacak K., and Eisenhofer G. Pheochromocytoma crisis induced by glucocorticoids: a report of four cases and review of the literature. Eur J Endocrinol 158 (2008) 423-429
25. Eisenhofer G., Rivers G., Rosas A.L., Quezado Z., Manger W.M., and Pacak K. Adverse drug reactions in patients with phaeochromocytoma: incidence, prevention and management. Drug Saf 30 (2007) 1031-1062
26. Lenders J.W., Pacak K., and Eisenhofer G. New advances in the biochemical diagnosis of pheochromocytoma: moving beyond catecholamines. Ann N Y Acad Sci 970 (2002) 29-40
27. Lenders J.W., Pacak K., Walther M.M., Linehan W.M., Mannelli M., Friberg P., et al. Biochemical diagnosis of pheochromocytoma: which test is best?. JAMA 287 (2002) 1427-1434
28. Eisenhofer G., Lenders J.W., Linehan W.M., Walther M.M., Goldstein D.S., and Keiser H.R. Plasma normetanephrine and metanephrine for detecting pheochromocytoma in von Hippel-Lindau disease and multiple endocrine neoplasia type 2. N Engl J Med 340 (1999) 1872-1879
29. Algeciras-Schimnich A., Preissner C.M., Young Jr. W.F., Singh R.J., and Grebe S.K. Plasma chromogranin A or urine fractionated metanephrines follow-up testing improves the diagnostic accuracy of plasma fractionated metanephrines for pheochromocytoma. J Clin Endocrinol Metab 93 (2008) 91-95
30. Canale M.P., and Bravo E.L. Diagnostic specificity of serum chromogranin-A for pheochromocytoma in patients with renal dysfunction. J Clin Endocrinol Metab 78 (1994) 1139-1144
31. Kimura N., Miura W., Noshiro T., Mizunashi K., Hanew K., Shimizu K., et al. Plasma chromogranin A in pheochromocytoma, primary hyperparathyroidism and pituitary adenoma in comparison with catecholamine, parathyroid hormone and pituitary hormones. Endocr J 44 (1997) 319-327
32. Cleary S., Phillips J.K., Huynh T.T., Pacak K., Fliedner S., Elkahloun A.G., et al. Chromogranin a expression in phaeochromocytomas associated with von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2. Horm Metab Res 39 (2007) 876-883
33. Tropea F., Baldari S., Restifo G., Fiorillo M.T., Surace P., and Herberg A. Evaluation of chromogranin A expression in patients with non-neuroendocrine tumours. Clin Drug Investig 26 (2006) 715-722
34. Ilias I., and Pacak K. Anatomical and functional imaging of metastatic pheochromocytoma. Ann N Y Acad Sci 1018 (2004) 495-504
35. Sisson J.C., Frager M.S., Valk T.W., Gross M.D., Swanson D.P., Wieland D.M., et al. Scintigraphic localization of pheochromocytoma. N Engl J Med 305 (1981) 12-17
36. Tsuchimochi S., Nakajo M., Nakabeppu Y., and Tani A. Metastatic pulmonary pheochromocytomas: positive I-123 MIBG SPECT with negative I-131 MIBG and equivocal I-123 MIBG planar imaging. Clin Nucl Med 22 (1997) 687-690
37. 123I-metaiodobenzylguanidine (MIBG) scan in a patient with angiomyolipoma; positive MIBG scan does not necessarily indicate the presence of pheochromocytoma. Intern Med 46 (2007) 1717-1721
38. Timmers H.J., Kozupa A., Chen C.C., Carrasquillo J.A., Ling A., Eisenhofer G., et al. Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma. J Clin Oncol 25 (2007) 2262-2269
39. 18F-fluorodopamine PET. J Nucl Med 48 (2007) 1940-1944
40. Zelinka T., Timmers H.J., Kozupa A., Chen C.C., Carrasquillo J.A., Reynolds J.C., et al. Role of positron emission tomography and bone scintigraphy in the evaluation of bone involvement in metastatic pheochromocytoma and paraganglioma: specific implications for succinate dehydrogenase enzyme subunit B gene mutations. Endocr Relat Cancer 15 (2008) 311-323
41. Bessell-Browne R., and O'Malley M.E. CT of pheochromocytoma and paraganglioma: risk of adverse events with i.v. administration of nonionic contrast material. Am J Roentgenol 188 (2007) 970-974
42. 131I-meta-iodobenzylguanidine kinetics in malignant phaeochromocytoma. Eur J Nucl Med 14 (1988) 345-348
43. Khafagi F.A., Shapiro B., Fig L.M., Mallette S., and Sisson J.C. Labetalol reduces iodine-131 MIBG uptake by pheochromocytoma and normal tissues. J Nucl Med 30 (1989) 481-489
44. Minami T., Adachi T., and Fukuda K. An effective use of magnesium sulfate for intraoperative management of laparoscopic adrenalectomy for pheochromocytoma in a pediatric patient. Anesth Analg 95 (2002) 1243-1244 table of contents
45. Bukowski R.M., and Vidt D.G. Chemotherapy trials in malignant pheochromocytoma: report of two patients and review of the literature. J Surg Oncol 27 (1984) 89-92
46. Lewi H.J., Reid R., Mucci B., Davidson J.K., Kyle K.F., Macpherson S.G., et al. Malignant phaeochromocytoma. Br J Urol 57 (1985) 394-398
47. Drasin H. Treatment of malignant pheochromocytoma. West J Med 128 (1978) 106-111
48. Averbuch S.D., Steakley C.S., Young R.C., Gelmann E.P., Goldstein D.S., Stull R., et al. Malignant pheochromocytoma: effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine. Ann Intern Med 109 (1988) 267-273
49. Koshihara K., Komiya I., Watanabe M., Maeda M., Fukushima N., Hoshihara Y., et al. Remarkable regression of malignant paraganglioma in the retroperitoneum and neck after chemotherapy: report of a case and a review of the literature. Jpn J Med 28 (1989) 772-776
50. Short J.H., and Darby T.D. Sympathetic nervous system blocking agents: 3. Derivatives of benzylguanidine. J Med Chem 10 (1967) 833-840
51. 131I] meta-iodobenzylguanidine: concise communication. J Nucl Med 22 (1981) 358-364
52. 131I]iodobenzylguanidine. J Nucl Med 21 (1980) 349-353
53. Tobes M.C., Jaques Jr. S., Wieland D.M., and Sisson J.C. Effect of uptake-one inhibitors on the uptake of norepinephrine and metaiodobenzylguanidine. J Nucl Med 26 (1985) 897-907
54. Shapiro B., Copp J.E., Sisson J.C., Eyre P.L., Wallis J., and Beierwaltes W.H. Iodine-131 metaiodobenzylguanidine for the locating of suspected pheochromocytoma: experience in 400 cases. J Nucl Med 26 (1985) 576-585
55. Geatti O., Shapiro B., Sisson J.C., Hutchinson R.J., Mallette S., Eyre P., et al. Iodine-131 metaiodobenzylguanidine scintigraphy for the location of neuroblastoma: preliminary experience in ten cases. J Nucl Med 26 (1985) 736-742
56. 131I)benzylguanidine in neuroblastoma. Am J Roentgenol 143 (1984) 373-374
57. Kimmig B., Brandeis W.E., Eisenhut M., Bubeck B., Hermann H.J., and zum Winkel K. Scintigraphy of a neuroblastoma with I-131 meta-iodobenzylguanidine. J Nucl Med 25 (1984) 773-775
58. 131I-Meta-iodobenzylguanidine scintigraphy of neuroblastomas. Semin Nucl Med 15 (1985) 154-160
59. Sisson J.C., Shapiro B., Beierwaltes W.H., Glowniak J.V., Nakajo M., Mangner T.J., et al. Radiopharmaceutical treatment of malignant pheochromocytoma. J Nucl Med 25 (1984) 197-206
60. Charbonnel B., Chatal J.F., Brendel A.J., Lanehche B., Lumbroso J., Marchandise X., et al. Treatment of malignant pheochromocytoma by 131-I-metaiodobenzylguanidine. Ann Endocrinol (Paris) 49 (1988) 344-347
61. Brendel A.J., Jeandot R., Guyot M., Lambert B., and Drouillard J. Radionuclide therapy of pheochromocytomas and neuroblastomas using iodine-131 metaiodobenzylguanidine (MIBG). Clin Nucl Med 14 (1989) 19-21
62. Troncone L., Rufini V., Montemaggi P., Danza F.M., Lasorella A., and Mastrangelo R. The diagnostic and therapeutic utility of radioiodinated metaiodobenzylguanidine (MIBG). 5 years of experience. Eur J Nucl Med 16 (1990) 325-335
63. Mukherjee J.J., Kaltsas G.A., Islam N., Plowman P.N., Foley R., Hikmat J., et al. Treatment of metastatic carcinoid tumours, phaeochromocytoma, paraganglioma and medullary carcinoma of the thyroid with (131)I-meta-iodobenzylguanidine [(131)I-mIBG]. Clin Endocrinol (Oxf) 55 (2001) 47-60
64. Safford S.D., Coleman R.E., Gockerman J.P., Moore J., Feldman J.M., Leight Jr. G.S., et al. Iodine-131 metaiodobenzylguanidine is an effective treatment for malignant pheochromocytoma and paraganglioma. Surgery 134 (2003) 956-962 discussion 962-3
65. Gedik G.K., Hoefnagel C.A., Bais E., and Valdes Olmos R.A. (131)I-MIBG Therapy in metastatic phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging 35 (2008) 725-733
66. 131I-MIBG): a comprehensive review of 116 reported patients. J Endocrinol Invest 20 (1997) 648-658
67. 131I]iodobenzylguanidine. J Nucl Med 25 (1984) 2-6
68. 131I-MIBG for refractory neuroblastoma. Pediatr Blood Cancer 44 (2005) 232-239
69. Citak E.C., Kesik V., Atay A.A., Sari E., Kismet E., and Koseoglu V. Transfusion-related acute lung injury in a child with neuroblastoma during a late engraftment period of autologous stem cell transplantation. Pediatr Transplant 12 (2008) 235-237
70. 131I-metaiodobenzylguanidine therapy for relapsed neuroblastoma. J Pediatr Hematol Oncol 25 (2003) 543-547
71. Afessa B., and Peters S.G. Noninfectious pneumonitis after blood and marrow transplant. Curr Opin Oncol 20 (2008) 227-233
72. 131I-MIBG). Ann N Y Acad Sci 1073 (2006) 465-490